R&D channel feed – Endpoints News

R&D channel feed

Pivoting to ‘ADC-like’ approach, Versant-backed startup gets $90M Series C

11 months ago

Paxlovid did not beat placebo in Stanford-led long Covid study

11 months ago

Kyowa Kirin invests $530M in first manufacturing site in North America

11 months ago

Oculis touts Phase 2 results in dry eye disease, but most data aren't statistically significant

11 months ago

Skye's stock sinks following eye disease failure as company shifts focus to obesity

11 months ago

Moderna’s Covid and flu combo vaccine succeeds in Phase 3 study

11 months ago

AbbVie and Alphabet's Calico added to Operation Warp Speed for rare diseases

11 months ago

Neuroscience company Rapport Therapeutics lists on Nasdaq

11 months ago

Aligos, Arbutus and others tout early hepatitis efficacy data at #EASL24

11 months ago

Ipsen returns to Marengo Therapeutics for new trispecific deal

11 months ago

Boehringer Ingelheim, Zealand tout key fibrosis data from mid-stage MASH trial

11 months ago

Biomea’s early-stage diabetes drug put on full clinical hold, stock crashes

11 months ago

AbbVie gets first taste of Elahere potential with new mid-stage win

11 months ago

Boehringer Ingelheim, Zealand’s positive Phase 2 MASH fibrosis data ‘unintentionally’ released

11 months ago

Moderna’s mRNA candidate picked for FDA’s Operation Warp Speed for rare diseases

11 months ago

Former Sanofi R&D leader Frank Nestle to lead Deerfield’s growing drug discovery arm

11 months ago

Lilly exec says developing new therapies for lupus is 'in scope'

11 months ago

Amgen's Uplizna succeeds in Phase 3 trial for rare autoimmune disease

11 months ago

RayzeBio warned of potential isotope supply issues before BMS deal

11 months ago

Radiopharmaceutical company Telix aims for $202M IPO

11 months ago

BioNTech co-founder Özlem Türeci on ‘hip’ ADCs and the power of combo therapies

11 months ago

Updated: Lilly details mid-stage win for tirzepatide in MASH with fibrosis data

11 months ago

Vir's early Phase 2 hepatitis D data show reduction, removal of virus with combo and monotherapy

11 months ago

Viking expands on Phase 2b data for NASH drug, touting histological endpoints

11 months ago

First page Previous page 38 39 404142 43 44 Next page Last page